Head-to-head evidence
ecnoglutide vs HRS-7535
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
ecnoglutide
Marketed by Sciwind Biosciences
NCT05813795 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled Phase 3 trial in 664 adults with overweight or obesity. Ecnoglutide 2.4 mg produced a significantly greater reduction in body weight than placebo at week 40, -13.2% vs +0.1%, p<0.0001, meeting the trial primary comparison.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT07553299 (registry estimate)
HRS-7535
Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals
NCT06904105 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial (n=556). The primary endpoint, percent weight change at week 44, was met: participants lost 9.5% (120 mg) and 10.9% (180 mg) of body weight versus 2.5% with placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT06820099 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ecnoglutide's landscape · HRS-7535's landscape